$61.74
0.400.65%
At close: -
$61.74
0.000.00%
After Hours: 4:00 PM EDT
Comments
Loading...
Rhythm Pharmaceuticals Analyst Ratings and Price Targets | NASDAQ:RYTM | Benzinga
Rhythm Pharmaceuticals Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Rhythm Pharmaceuticals Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
B of A Securities
HC Wainwright & Co.
Canaccord Genuity
Needham
Wells Fargo
1calculated from analyst ratings
Analyst Ratings for Rhythm Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/10/2025 | Buy Now | — | B of A Securities | Tazeen Ahmad55% | $63 → $68 | Maintains | Buy | Get Alert |
| 04/08/2025 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju42% | $70 → $80 | Reiterates | Buy → Buy | Get Alert |
| 04/08/2025 | Buy Now | — | Canaccord Genuity | Whitney Ijem45% | $81 → $92 | Maintains | Buy | Get Alert |
| 04/08/2025 | Buy Now | — | Needham | Joseph Stringer58% | $66 → $66 | Reiterates | Buy → Buy | Get Alert |
| 04/07/2025 | Buy Now | — | Wells Fargo | Derek Archila57% | $80 → $91 | Maintains | Overweight | Get Alert |
| 03/24/2025 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju42% | $70 → $70 | Reiterates | Buy → Buy | Get Alert |
| 03/18/2025 | Buy Now | — | Needham | Joseph Stringer58% | $64 → $66 | Maintains | Buy | Get Alert |
| 03/07/2025 | Buy Now | — | Morgan Stanley | Jeffrey Hung50% | $72 → $72 | Assumes | → Overweight | Get Alert |
| 03/05/2025 | Buy Now | — | Stifel | Paul Matteis41% | → $78 | Reinstates | → Buy | Get Alert |
| 03/03/2025 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju42% | $69 → $70 | Maintains | Buy | Get Alert |
| 02/27/2025 | Buy Now | — | Canaccord Genuity | Whitney Ijem45% | $80 → $81 | Maintains | Buy | Get Alert |
| 02/27/2025 | Buy Now | — | Needham | Joseph Stringer58% | $64 → $64 | Reiterates | Buy → Buy | Get Alert |
| 02/24/2025 | Buy Now | — | Needham | Joseph Stringer58% | $64 → $64 | Reiterates | Buy → Buy | Get Alert |
| 02/19/2025 | Buy Now | — | Needham | Joseph Stringer58% | $64 → $64 | Reiterates | Buy → Buy | Get Alert |
| 12/23/2024 | Buy Now | — | JMP Securities | Jonathan Wolleben65% | $75 → $75 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 12/23/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju42% | $69 → $69 | Reiterates | Buy → Buy | Get Alert |
| 12/20/2024 | Buy Now | — | Oppenheimer | Leland Gershell68% | → $76 | Initiates | → Outperform | Get Alert |
| 12/05/2024 | Buy Now | — | Goldman Sachs | Corinne Jenkins48% | $59 → $66 | Maintains | Buy | Get Alert |
| 12/04/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju42% | $69 → $69 | Reiterates | Buy → Buy | Get Alert |
| 11/25/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju42% | $69 → $69 | Reiterates | Buy → Buy | Get Alert |
| 11/19/2024 | Buy Now | — | Canaccord Genuity | Whitney Ijem45% | $80 → $80 | Maintains | Buy | Get Alert |
| 11/07/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju42% | $64 → $69 | Maintains | Buy | Get Alert |
| 11/06/2024 | Buy Now | — | Canaccord Genuity | Whitney Ijem45% | $77 → $80 | Maintains | Buy | Get Alert |
| 11/06/2024 | Buy Now | — | TD Cowen | Phil Nadeau66% | $55 → $65 | Maintains | Buy | Get Alert |
| 11/06/2024 | Buy Now | — | Needham | Joseph Stringer58% | $55 → $64 | Maintains | Buy | Get Alert |
| 10/30/2024 | Buy Now | — | Needham | Joseph Stringer58% | $55 → $55 | Reiterates | Buy → Buy | Get Alert |
| 10/25/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju42% | $64 → $64 | Reiterates | Buy → Buy | Get Alert |
| 10/21/2024 | Buy Now | — | Guggenheim | Seamus Fernandez57% | → $70 | Initiates | → Buy | Get Alert |
| 10/14/2024 | Buy Now | — | B of A Securities | Tazeen Ahmad55% | $48 → $52 | Maintains | Neutral | Get Alert |
| 10/07/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju42% | $64 → $64 | Reiterates | Buy → Buy | Get Alert |
| 09/18/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju42% | → $64 | Initiates | → Buy | Get Alert |
| 09/17/2024 | Buy Now | — | JMP Securities | Jonathan Wolleben65% | → $64 | Initiates | → Market Outperform | Get Alert |
| 08/07/2024 | Buy Now | — | Needham | Joseph Stringer58% | $55 → $55 | Reiterates | Buy → Buy | Get Alert |
| 07/25/2024 | Buy Now | — | Needham | Joseph Stringer58% | $46 → $55 | Maintains | Buy | Get Alert |
| 05/08/2024 | Buy Now | — | Canaccord Genuity | Whitney Ijem45% | $80 → $79 | Maintains | Buy | Get Alert |
| 05/08/2024 | Buy Now | — | B of A Securities | Tazeen Ahmad55% | $49 → $42 | Downgrade | Buy → Neutral | Get Alert |
| 05/07/2024 | Buy Now | — | Needham | Joseph Stringer58% | $50 → $46 | Maintains | Buy | Get Alert |
| 04/26/2024 | Buy Now | — | Needham | Joseph Stringer58% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 04/18/2024 | Buy Now | — | Wells Fargo | Derek Archila57% | $53 → $52 | Maintains | Overweight | Get Alert |
| 04/10/2024 | Buy Now | — | Needham | Joseph Stringer58% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 02/22/2024 | Buy Now | — | Needham | Joseph Stringer58% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 01/26/2024 | Buy Now | — | Needham | Joseph Stringer58% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 01/26/2024 | Buy Now | — | Goldman Sachs | Corinne Jenkins48% | $42 → $52 | Maintains | Buy | Get Alert |
| 01/25/2024 | Buy Now | — | Goldman Sachs | Corinne Jenkins48% | $42 → $52 | Maintains | Buy | Get Alert |
| 01/04/2024 | Buy Now | — | Needham | Joseph Stringer58% | $45 → $50 | Maintains | Buy | Get Alert |
| 12/19/2023 | Buy Now | — | Morgan Stanley | Jeffrey Hung50% | $29 → $55 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 12/19/2023 | Buy Now | — | Wells Fargo | Derek Archila57% | $48 → $53 | Maintains | Overweight | Get Alert |
| 12/07/2023 | Buy Now | — | Goldman Sachs | Corinne Jenkins48% | $38 → $42 | Maintains | Buy | Get Alert |
| 12/07/2023 | Buy Now | — | Needham | Joseph Stringer58% | $32 → $45 | Maintains | Buy | Get Alert |
| 11/08/2023 | Buy Now | — | Wells Fargo | Derek Archila57% | $38 → $40 | Maintains | Overweight | Get Alert |
| 10/10/2023 | Buy Now | — | Morgan Stanley | Jeffrey Hung50% | $28 → $29 | Maintains | Equal-Weight | Get Alert |
| 08/02/2023 | Buy Now | — | Morgan Stanley | Jeffrey Hung50% | $28 → $28 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
| 08/02/2023 | Buy Now | — | B of A Securities | Tazeen Ahmad55% | $22 → $27 | Upgrade | Neutral → Buy | Get Alert |
| 08/02/2023 | Buy Now | — | Needham | Joseph Stringer58% | → $32 | Reiterates | Buy → Buy | Get Alert |
| 06/20/2023 | Buy Now | — | Needham | Joseph Stringer58% | → $32 | Reiterates | Buy → Buy | Get Alert |
| 04/18/2023 | Buy Now | — | Needham | Joseph Stringer58% | → $32 | Reiterates | → Buy | Get Alert |
| 03/02/2023 | Buy Now | — | Morgan Stanley | Jeffrey Hung50% | $26 → $28 | Maintains | Equal-Weight | Get Alert |
| 03/02/2023 | Buy Now | — | Canaccord Genuity | Whitney Ijem45% | $52 → $56 | Maintains | Buy | Get Alert |
| 03/02/2023 | Buy Now | — | Goldman Sachs | Corinne Jenkins48% | $40 → $45 | Maintains | Buy | Get Alert |
| 03/02/2023 | Buy Now | — | Ladenburg Thalmann | Michael Higgins48% | → $35 | Reiterates | → Buy | Get Alert |
| 03/02/2023 | Buy Now | — | Needham | Joseph Stringer58% | → $32 | Reiterates | → Buy | Get Alert |
| 01/26/2023 | Buy Now | — | Goldman Sachs | Corinne Jenkins48% | $35 → $40 | Maintains | Buy | Get Alert |
| 01/18/2023 | Buy Now | — | Canaccord Genuity | Whitney Ijem45% | — | Assumes | → Buy | Get Alert |
| 11/10/2022 | Buy Now | — | Goldman Sachs | Graig Suvannavejh50% | $31 → $35 | Maintains | Buy | Get Alert |
| 11/09/2022 | Buy Now | — | Morgan Stanley | Jeffrey Hung50% | $16 → $26 | Maintains | Equal-Weight | Get Alert |
| 09/08/2022 | Buy Now | — | Goldman Sachs | Corinne Jenkins48% | $28 → $31 | Maintains | Buy | Get Alert |
| 08/08/2022 | Buy Now | — | Goldman Sachs | Corinne Jenkins48% | → $28 | Upgrade | Neutral → Buy | Get Alert |
| 08/05/2022 | Buy Now | — | B of A Securities | Tazeen Ahmad55% | $8 → $20 | Upgrade | Underperform → Neutral | Get Alert |
| 08/03/2022 | Buy Now | — | Morgan Stanley | Jeffrey Hung50% | $8 → $16 | Maintains | Equal-Weight | Get Alert |
| 07/15/2022 | Buy Now | — | Morgan Stanley | Jeffrey Hung50% | $4 → $8 | Maintains | Equal-Weight | Get Alert |
| 07/13/2022 | Buy Now | — | Goldman Sachs | Graig Suvannavejh50% | $4 → $6 | Maintains | Neutral | Get Alert |
| 06/17/2022 | Buy Now | — | Needham | Joseph Stringer58% | $40 → $25 | Maintains | Buy | Get Alert |
| 06/17/2022 | Buy Now | — | Stifel | Dae Gon Ha46% | $23 → $25 | Maintains | Buy | Get Alert |
| 06/07/2022 | Buy Now | — | Morgan Stanley | Jeffrey Hung50% | $12 → $4 | Maintains | Equal-Weight | Get Alert |
| 05/24/2022 | Buy Now | — | Goldman Sachs | Graig Suvannavejh50% | $8 → $7 | Maintains | Neutral | Get Alert |
FAQ
What is the target price for Rhythm Pharmaceuticals (RYTM) stock?
The latest price target for Rhythm Pharmaceuticals (NASDAQ:RYTM) was reported by B of A Securities on April 10, 2025. The analyst firm set a price target for $68.00 expecting RYTM to rise to within 12 months (a possible 10.14% upside). 38 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Rhythm Pharmaceuticals (RYTM)?
The latest analyst rating for Rhythm Pharmaceuticals (NASDAQ:RYTM) was provided by B of A Securities, and Rhythm Pharmaceuticals maintained their buy rating.
When was the last upgrade for Rhythm Pharmaceuticals (RYTM)?
The last upgrade for Rhythm Pharmaceuticals Inc happened on December 19, 2023 when Morgan Stanley raised their price target to $55. Morgan Stanley previously had an equal-weight for Rhythm Pharmaceuticals Inc.
When was the last downgrade for Rhythm Pharmaceuticals (RYTM)?
The last downgrade for Rhythm Pharmaceuticals Inc happened on May 8, 2024 when B of A Securities changed their price target from $49 to $42 for Rhythm Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Rhythm Pharmaceuticals (RYTM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Rhythm Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Rhythm Pharmaceuticals was filed on April 10, 2025 so you should expect the next rating to be made available sometime around April 10, 2026.
Is the Analyst Rating Rhythm Pharmaceuticals (RYTM) correct?
While ratings are subjective and will change, the latest Rhythm Pharmaceuticals (RYTM) rating was a maintained with a price target of $63.00 to $68.00. The current price Rhythm Pharmaceuticals (RYTM) is trading at is $61.74, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
